Browse by People


Up a level
Export as [feed] RSS [feed] RSS 2.0 Short Author List
Number of items: 17.


Wainstein, Marina, Spyrison, Nicholas, Dai, Danyang, Ghadimi, Moji, Chávez-Iñiguez, Jonathan S, Rizo-Topete, Lilia, Citarella, Barbara Wanjiru, Merson, Laura, Pole, Jason D, Claure-Del Granado, Rolando
et al (show 1435 more authors) (2023) Association of Country Income Level With the Characteristics and Outcomes of Critically Ill Patients Hospitalized With Acute Kidney Injury and COVID-19. Kidney International Reports, 8 (8). pp. 1514-1530.


Horby, Peter W, Emberson, Jonathan R, Mafham, Marion, Campbell, Mark, Peto, Leon, Pessoa-Amorim, Guilhenne, Spata, Enti, Staplin, Natalie, Lowe, Catherine, Chadwick, David R
et al (show 23 more authors) (2022) Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. LANCET, 400 (10349). pp. 359-368.


Abdukahil, Sheryl Ann, Abe, Ryuzo, Abel, Laurent, Absil, Lara, Acker, Andrew, Adachi, Shingo, Adam, Elisabeth, Adriao, Diana, Ainscough, Kate, Hssain, Ali Ait
et al (show 1056 more authors) (2021) COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study. INFECTION, 49 (5). pp. 889-905.


Horby, Peter W, Mafham, Marion, Peto, Leon, Campbell, Mark, Pessoa-Amorim, Guilherme, Spata, Enti, Staplin, Natalie, Emberson, Jonathan R, Prudon, Benjamin, Hine, Paul
et al (show 22 more authors) (2022) Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. LANCET, 399 (10325). pp. 665-676.


Gupta, Rishi K, Harrison, Ewen M, Ho, Antonia, Docherty, Annemarie B, Knight, Stephen R, van Smeden, Maarten, Abubakar, Ibrahim, Lipman, Marc, Quartagno, Matteo, Pius, Riinu
et al (show 30 more authors) (2021) Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study. LANCET RESPIRATORY MEDICINE, 9 (4). pp. 349-359.


Emary, Katherine RW, Golubchik, Tanya, Aley, Parvinder K, Ariani, Cristina V, Angus, Brian, Bibi, Sagida, Blane, Beth, Bonsall, David, Cicconi, Paola, Charlton, Sue
et al (show 57 more authors) (2021) Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. LANCET, 397 (10282). pp. 1351-1362.


Docherty, Annemarie B, Harrison, Ewen M, Green, Christopher A, Hardwick, Hayley E, Pius, Riinu, Norman, Lisa, Holden, Karl A, Read, Jonathan M, Dondelinger, Frank, Carson, Gail
et al (show 16 more authors) (2020) Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ (Clinical research ed.), 369. m1985-.


Liu, Xinxue, Wright, Annie, Feng, Shuo, Janani, Leila, Aley, Parvinder K, Babbage, Gavin, Baker, Jonathan, Baxter, David, Bawa, Tanveer, Bula, Marcin
et al (show 50 more authors) (2023) Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial. JOURNAL OF INFECTION, 87 (1). pp. 18-26.


Liu, Xinxue, Munro, Alasdair PS, Feng, Shuo, Janani, Leila, Aley, Parvinder K, Babbage, Gavin, Baxter, David, Bula, Marcin, Cathie, Katrina, Chatterjee, Krishna
et al (show 48 more authors) (2022) Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial. JOURNAL OF INFECTION, 84 (6). pp. 795-813.


Liu, Xinxue, Munro, Alasdair PS, Feng, Shuo, Janani, Leila, Aley, Parvinder K, Babbage, Gavin, Baxter, David, Bula, Marcin, Cathie, Katrina, Chatterjee, Krishna
et al (show 48 more authors) (2023) Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial (vol 84, pg 795, 2022). JOURNAL OF INFECTION, 86 (5). pp. 540-541.


Relph, Katharine A, Russell, Clark D, Fairfield, Cameron J, Turtle, Lance, de Silva, Thushan I, Siggins, Matthew K, Drake, Thomas M, Thwaites, Ryan S, Abrams, Simon, Moore, Shona C
et al (show 358 more authors) (2022) Procalcitonin Is Not a Reliable Biomarker of Bacterial Coinfection in People With Coronavirus Disease 2019 Undergoing Microbiological Investigation at the Time of Hospital Admission. Open Forum Infectious Diseases, 9 (5). ofac179-.


Knight, Stephen R, Gupta, Rishi K, Ho, Antonia, Pius, Riinu, Buchan, Iain ORCID: 0000-0003-3392-1650, Carson, Gail, Drake, Thomas M, Dunning, Jake, Fairfield, Cameron J, Gamble, Carrol ORCID: 0000-0002-3021-1955
et al (show 25 more authors) (2022) Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. THORAX, 77 (6). pp. 606-615.


Knight, Stephen R, Ho, Antonia, Pius, Riinu, Buchan, Iain ORCID: 0000-0003-3392-1650, Carson, Gail, Drake, Thomas M, Dunning, Jake, Fairfield, Cameron J, Gamble, Carrol ORCID: 0000-0002-3021-1955, Green, Christopher A
et al (show 26 more authors) (2020) Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. BMJ: British Medical Journal, 370. m3339-.


Winslow, Rebecca L, Zhou, Jie, Windle, Ella F, Nur, Intesar, Lall, Ranjit, Ji, Chen, Millar, Jonathan Edward, Dark, Paul M, Naisbitt, Jay, Simonds, Anita
et al (show 7 more authors) (2022) SARS-CoV-2 environmental contamination from hospitalised patients with COVID-19 receiving aerosol-generating procedures. THORAX, 77 (3). pp. 259-267.


Munro, Alasdair PS, Janani, Leila, Cornelius, Victoria, Aley, Parvinder K, Babbage, Gavin, Baxter, David, Bula, Marcin, Cathie, Katrina, Chatterjee, Krishna, Dodd, Kate
et al (show 44 more authors) (2021) Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. LANCET, 398 (10318). pp. 2258-2276.


Munro, Alasdair PS, Feng, Shuo, Janani, Leila, Cornelius, Victoria, Aley, Parvinder K, Babbage, Gavin, Baxter, David, Bula, Marcin, Cathie, Katrina, Chatterjee, Krishna
et al (show 45 more authors) (2022) Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. LANCET INFECTIOUS DISEASES, 22 (8). pp. 1131-1141.


Griffee, Matthew J, Bozza, Patricia T, Reyes, Luis Felipe, Eddington, Devin P, Rosenberger, Dorothea, Merson, Laura, Citarella, Barbara Wanjiru, Fanning, Jonathon P, Alexander, Peta MA, Fraser, John
et al (show 1499 more authors) (2023) Thrombotic and hemorrhagic complications of COVID-19 in adults hospitalized in high-income countries compared with those in adults hospitalized in low- and middle-income countries in an international registry. Research and Practice in Thrombosis and Haemostasis, 7 (5). p. 102142.

This list was generated on Mon Mar 18 17:19:24 2024 GMT.